Safety and Effectiveness of Giving Indinavir and Nelfinavir to HIV-Infected Patients

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to see if it is safe and effective to treat HIV-infected patients with indinavir (IDV) plus nelfinavir (NFV), 2 anti-HIV medications.

It is thought that IDV plus NFV will be a safe drug combination for treating HIV.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Indinavir; Nelfinavir

Criteria

Inclusion Criteria

You may be eligible for this study if you:

• Are HIV-positive.

• Have a CD4 count of at least 100 cells/mm3.

• Have a plasma viral load (level of HIV in the blood) of at least 30,000 copies/ml.

• Are at least 18 years old.

Exclusion Criteria

You will not be eligible for this study if you:

• Have ever been treated with any protease inhibitors (PIs).